Quantitative Concept – Page 4

Berkeley startup raises $106.5M for all‑RNA ‘jumping gene’ therapies

1 month ago talkbio0Tagged Berkeley, Cells, Funding, gene therapy, jumping gene, M financing, programmable RNA medicines, Radar Therapeutics, RNA gene, Series A

Radar Therapeutics; Berkeley startup; $106.5M financing; Series A; jumping gene; RNA gene insertion; programmable RNA medicines; cell and gene therapy; biotech funding

Pilatus Raises $14M for First-in-Human Study of Anti-CD36 mAb

1 month ago talkbio0Tagged Anti-CD36 mAb, First-in-Human Study, Funding, Pilatus

Pilatus; funding; anti-CD36 mAb; first-in-human study; biotech

NeOnc Technologies Reports Updated Clinical Results for Intranasal NEO100

1 month ago talkbio0Tagged Central Nervous System Neoplasms, clinical results, Compassionate Use, Intranasal approach, NEO100, NeOnc Technologies, NTHI, Overall Survival, Phase 1/2a trial, radiographic remission, recurrent astrocytoma, World Health Organization

NeOnc Technologies; NTHI; NEO100; intranasal NEO100; updated clinical results; recurrent astrocytoma; WHO Grade III/IV; radiographic remission; overall survival; compassionate use; Phase 1/2a trial; CNS cancers

Sanofi’s multiple sclerosis drug tolebrutinib flunks Phase 3 in PPMS and faces another FDA PDUFA delay

1 month ago talkbio0Tagged BTK inhibitor, Clinical trial failure, Deferred, Mississippi (geographic location), Multiple Sclerosis, non-relapsing secondary progressive, nrSPMS, Parts per million (qualifier value), PDUFA, Progressive, Regulatory Setback, Review [Publication Type], sanofi, Tolebrutinib, United States Food and Drug Administration

Sanofi; tolebrutinib; multiple sclerosis; primary progressive multiple sclerosis; PPMS; non-relapsing secondary progressive MS; nrSPMS; Phase 3 PERSEUS trial; PDUFA delay; FDA review; BTK inhibitor; clinical trial failure; regulatory setback

Immunome’s desmoid tumor drug varegacestat posts landmark Phase 3 results, setting up a potential challenge to Merck KGaA’s Ogsiveo

1 month ago talkbio0Tagged Fibromatosis, Aggressive, Frequency of Responses, gamma secretase inhibitor, Immunome, Infrequent, Merck KGaA, NDA, Neoplasms, Ogsiveo, Phase 3 RINGSIDE trial, Progression-Free Survival, varegacestat

Immunome; varegacestat; desmoid tumors; Phase 3 RINGSIDE trial; gamma secretase inhibitor; Merck KGaA; Ogsiveo; progression-free survival; objective response rate; rare tumors; oncology; NDA filing

Scaling for a New Era: The Rise of Radiopharma

1 month ago talkbio0Tagged Clinical Trials, CROs, Diagnostics, Funding, Lutetium-177, M&A, Neoplasms, Pet Animal, precision oncology, radioligand therapy, Radiopharmaceuticals, radiotheranostics, Research Infrastructure, supply chain, targeted alpha therapy

radiopharmaceuticals; radioligand therapy; oncology; precision oncology; targeted alpha therapy; Lutetium-177; Actinium-225; clinical trials; radiotheranostics; M&A; biotech funding; supply chain; infrastructure; CROs; companion diagnostics

‘Au Revoir TIGIT’: Gilead, Arcus Cut Gastro Cancer Drug After Late-Stage Failure

1 month ago talkbio0Tagged Arcus Biosciences, casdatifan, domvanalimab, EDGE-Gastric, Esophageal Neoplasms, Failure (biologic function), Gilead Sciences, immuno-oncology, Malignant neoplasm of stomach, nivolumab, Opdivo, Overall Survival, Phase 3 trial, STAR-221, TIGIT gene, zimberelimab

domvanalimab; TIGIT; Gilead Sciences; Arcus Biosciences; STAR-221; gastric cancer; esophageal cancer; zimberelimab; Opdivo (nivolumab); Phase 3 trial failure; overall survival; casdatifan; immuno-oncology; EDGE-Gastric

Pfizer’s Tukysa Shows Strong PFS Benefit in First-Line HER2+ Breast Cancer Maintenance at SABCS 2025, Sparking Debate with Enhertu

2 months ago talkbio0Tagged Enhertu, first-line maintenance, HER2-positive carcinoma of breast, HER2CLIMB-05, Pfizer, Progression-Free Survival, SABCS, Tukysa

Tukysa; Pfizer; HER2-positive breast cancer; SABCS 2025; HER2CLIMB-05; progression-free survival; Enhertu; first-line maintenance

Roche breast cancer pill cuts post-surgery recurrence risk by 30% in major trial

2 months ago talkbio0Tagged Adjuvant Therapy, Disease-Free Survival, ER-positive, giredestrant, HER2-negative, hormone receptor-positive, Hormone Therapy, Malignant neoplasm of breast, Oral SERD, phase III lidERA trial, Recurrence Risk, Roche (company), San Antonio Breast Cancer Symposium

Roche; giredestrant; breast cancer; hormone receptor-positive; ER-positive; HER2-negative; oral SERD; endocrine therapy; adjuvant therapy; recurrence risk; phase III lidERA trial; disease-free survival; San Antonio Breast Cancer Symposium

Updated Efficacy Data of Ivonescimab Plus Chemotherapy as First-Line Treatment for TNBC at ESMO IO 2025

2 months ago talkbio0Tagged AK112 - 308, Breakthrough Therapy Designation, Combined, Complex partial seizures, disease control rate, ESMO IO, First line treatment, Frequency of Responses, HARMONi-BC1, Ivonescimab, PD-1/VEGF bispecific antibody, PD-L1, Pharmacotherapy, Phase 2 Clinical Trials, Progression-Free Survival, safety profile, Subgroup A Nepoviruses, TNBC, Triple Negative Breast Neoplasms, Yidafan

ivonescimab; Yidafan; PD-1/VEGF bispecific antibody; triple-negative breast cancer; TNBC; first-line treatment; ESMO IO 2025; Phase II trial; chemotherapy combination; objective response rate; progression-free survival; disease control rate; PD-L1 CPS subgroups; safety profile; Breakthrough Therapy Designation; HARMONi-BC1; AK112-308